Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis

• Published in: Scientific reports 2022-08, Vol.12 (1), p.14221-11, Article 14221
• Main Authors: Kozma, Kincső, Dömötör, Zsuzsa Réka, Csutak, Adrienne, Szabó, László, Hegyi, Péter, Erőss, Bálint, Helyes, Zsuzsanna, Molnár, Zsolt, Dembrovszky, Fanni, Szalai, Eszter
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; 631/67; 692/4028; Administration, Topical; Carcinoma, Squamous Cell - pathology; Conjunctival Neoplasms - drug therapy; Conjunctival Neoplasms - pathology; Conjunctival Neoplasms - surgery; Drug therapy; Eye; Eye Neoplasms - drug therapy; Eye Neoplasms - pathology; Eye Neoplasms - surgery; Fluorouracil; Humanities and Social Sciences; Humans; Interferon alpha-2; Meta-analysis; Mitomycin; Mitomycin C; multidisciplinary; Patients; Retrospective Studies; Science; Science (multidisciplinary); Side effects; Squamous cell carcinoma; Treatment Outcome; Tumors; α-Interferon
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-18545-6

Ocular surface squamous neoplasia (OSSN) has different treatment modalities. Although surgical excision has been the gold standard therapeutic option, topical pharmacotherapy agents such as 5-fluorouracil (5-FU), interferon alfa-2b (IFN) and mitomycin-C (MMC) are also commonly used. The protocol was registered (CRD42021224961). Comprehensive literature research was carried out to compare topical pharmacotherapy (5-FU or IFN or MMC) to surgical excision regarding clinical success (tumor resolution), recurrence and complications in patients undergoing treatment for OSSN. From 7859 records, 7 articles were included in the qualitative and 4 in the quantitative synthesis. The outcomes of surgical excision and topical pharmacotherapy were comparable in the included articles. There were no significant differences between surgical excision and topical pharmacotherapy regarding the clinical success [odds ratio (OR): 0.785; confidence interval (CI): 0.130–4.736, P = 0.792)] and tumor recurrence (OR: 0.746; CI: 0.213–2.609; P = 0.646). The most common side effect of the different therapeutic options was dry eye. The highest rate of dry eye symptoms was reported after surgical excision (in 59%). Topical pharmacotherapy with all the 3 agents is as effective and well-tolerable as surgical excision in terms of tumor resolution, recurrence rate and side effects in all OSSN patients suggesting similar long-term clinical benefits.